Crystal violet and zinc oxide nanoparticles (CVZnO) were incorporated into medical grade polyurethane polymers by a two-step dipping procedure to prepare novel bactericidal surfaces. The photobactericidal activity of CVZnO polyurethane samples was tested against the Gram-positive bacterium, Staphylococcus aureus and the Gram-negative bacterium, Escherichia coli. Exposure of the polymer samples to white light induced the lethal photosensitisation of both S. aureus and E. coli. In addition, this novel system demonstrated significant antibacterial activity under dark conditions against S. aureus within 2 hours, but more remarkably, a 99.9% reduction in the numbers of E. coli within 4 hours in the dark. This is, to the best of our knowledge, the most potent 'dark-kill' by a light activated antimicrobial agent ever reported.The singlet oxygen quenchers, bovine serum albumin and L-histidine, and an enzyme which catalyses the decomposition of hydrogen peroxide, bovine catalase, were incorporated into the antibacterial assays to determine if the mechanism of E. coli kill involved a Type 1 or a Type 2 light-activated process.

A simple procedure to develop antibacterial surfaces using thiol-capped gold nanoparticles (AuNPs) is shown, which effectively kill bacteria under dark and light conditions. The effect of AuNP size and concentration on photo-activated antibacterial surfaces is reported and we show significant size effects, as well as bactericidal activity with crystal violet (CV) coated polyurethane. These materials have been proven to be powerful antibacterial surfaces against both Gram-positive and Gram-negative bacteria. AuNPs of 2, 3 or 5 nm diameter were swell-encapsulated into PU before a coating of CV was applied (known as PU-AuNPs-CV). The antibacterial activity of PU-AuNPs-CV samples was tested against Staphylococcus aureus and Escherichia coli as representative Gram-positive and Gram-negative bacteria under dark and light conditions. All light conditions in this study simulated a typical white-light hospital environment. This work demonstrates that the antibacterial activity of PU-AuNPs-CV samples and the synergistic enhancement of photoactivity of triarylmethane type dyes is highly dependent on nanoparticle size and concentration. The most powerful PU-AuNPs-CV antibacterial surfaces were achieved using 1.0 mg mL−1 swell encapsulation concentrations of 2 nm AuNPs. After two hours, Gram-positive and Gram-negative bacteria were reduced to below the detection limit (>4 log) under dark and light conditions.

A simple, easily up-scalable swell-encapsulation-shrink technique was used to incorporate small 2.5 nm copper nanoparticles (CuNPs) into two widely used medical grade polymers, polyurethane, and silicone, with no significant impact on polymer coloration. Both medical grade polymers with incorporated CuNPs demonstrated potent antimicrobial activity against the clinically relevant bacteria, methicillin-resistant Staphylococcus aureus and Escherichia coli. CuNP-incorporated silicone samples displayed potent antibacterial activity against both bacteria within 6 h. CuNP-incorporated polyurethane exhibited more efficacious antimicrobial activity, resulting in a 99.9% reduction in the numbers of both bacteria within just 2 h. With the high prevalence of hospital-acquired infections, the use of antimicrobial materials such as these CuNP-incorporated polymers could contribute to reducing microbial contamination associated with frequently touched surfaces in and around hospital wards (e.g., bed rails, overbed tables, push plates, etc.).

Healthcare-associated infections pose a serious risk for patients, staff, and visitors and are a severe burden on the National Health Service, costing at least £1 billion annually. Antimicrobial surfaces significantly contribute toward reducing the incidence of infections as they prevent bacterial adhesion and cause bacterial cell death. Using a simple, easily upscalable swell–encapsulation–shrink method, novel antimicrobial surfaces have been developed by incorporating metal oxide nanoparticles (NPs) and crystal violet (CV) dye into medical-grade polyurethane sheets. This study compares the bactericidal effects of polyurethane incorporating ZnO, Mg-doped ZnO, and MgO. All metal oxide NPs are well defined, with average diameters ranging from 2 to 18 nm. These materials demonstrate potent bactericidal activity when tested against clinically relevant bacteria such as Escherichia coli and Staphylococcus aureus. Additionally, these composites are tested against an epidemic strain of methicillin-resistant Staphylococcus aureus (MRSA) that is rife in hospitals throughout the UK. Furthermore, we have tested these materials using a low light intensity (∼500 lx), similar to that present in many clinical environments. The highest activity is achieved from polymer composites incorporating CV and ∼3 nm ZnO NPs, and the different performances of the metal oxides have been discussed.

Toluidine blue O (TBO) dye together with either silver (Ag) nanoparticles (NPs), gold (Au) NPs, or a mixture of Ag and Au NPs (Mix Ag–Au NPs) were incorporated into polyurethane to make antimicrobial surfaces using a swell-encapsulation-shrink process.

Silver thin films were deposited on SiO2-barrier-coated float glass, fluorine-doped tin oxide (FTO) glass, Activ glass, and TiO2-coated float glass via AACVD using silver nitrate at 350 °C. The films were annealed at 600 °C and analyzed by X-ray powder diffraction, X-ray photoelectron spectroscopy, UV/vis/near-IR spectroscopy, and scanning electron microscopy. All the films were crystalline, and the silver was present in its elemental form and of nanometer dimension. The antibacterial activity of these samples was tested against Escherichia coli and Staphylococcus aureus in the dark and under UV light (365 nm). All Ag-deposited films reduced the numbers of E. coli by 99.9% within 6 h and the numbers of S. aureus by 99.9% within only 2 h. FTO/Ag reduced bacterial numbers of E. coli to below the detection limit after 60 min and caused a 99.9% reduction of S. aureus within only 15 min of UV irradiation. Activ/Ag reduced the numbers of S. aureus by 66.6% after 60 min and TiO2/Ag killed 99.9% of S. aureus within 60 min of UV exposure. More remarkably, we observed a 99.9% reduction in the numbers of E. coli within 6 h and the numbers of S. aureus within 4 h in the dark using our novel TiO2/Ag system.

Although glutaraldehyde is known to be bactericidal in solution, its potential use to create novel antibacterial polymers suitable for use in healthcare environments has not been evaluated. Here, novel materials were prepared in which glutaraldehyde was either incorporated into polyurethane using a simple “swell‐encapsulation‐shrink” method (hereafter referred to as “glutaraldehyde‐impregnated polyurethane”), or simply applied to the polymer surface (hereafter referred to as “glutaraldehyde‐coated polyurethane”). The antibacterial activity of glutaraldehyde‐impregnated and glutaraldehyde‐coated polyurethane samples was tested against Escherichia coli and Staphylococcus aureus. Glutaraldehyde‐impregnated polyurethane resulted in a 99.9% reduction in the numbers of E. coli within 2 h and a similar reduction of S. aureus within 1 h, whereas only a minimal reduction in bacterial numbers was observed when the biocide was bound to the polymer surface. After 15 days, however, the bactericidal activity of the impregnated material was substantially reduced presumably due to polymerization of glutaraldehyde. Thus, although glutaraldehyde retains antibacterial activity when impregnated into polyurethane, activity is not maintained for extended periods of time. Future work should examine the potential of chemical modification of glutaraldehyde and/or polyurethane to improve the useful lifespan of this novel antibacterial polymer.

Hospital-acquired bacterial infections are a significant burden on healthcare systems worldwide causing increased duration of hospital stays and prolonged patient suffering. We show that polyurethane containing crystal violet (CV) and 3-4 nm zinc oxide nanoparticles (ZnO NPs) possesses excellent bactericidal activity against hospital-acquired pathogens including multidrug resistant Escherichia coli, Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA) and even against highly-resistant endospores of Clostridioides (Clostridium) difficile. Importantly, we used clinical isolates of bacterial strains, a protocol to mimic the environmental conditions of a real exposure in the healthcare setting and low light intensity equivalent to that encountered in UK hospitals (~500 lux). Our data shows that ZnO NPs enhance the photobactericidal activity of CV under low intensity light even with short exposure times and we show that this involves both Type I and Type II photochemical pathways. Interestingly, polyurethane containing ZnO NPs alone showed significant bactericidal activity in the dark against one strain of E. coli indicating that the NPs possess both lightactivated synergistic activity with CV and inherent bactericidal activity that is independent of light.These new antibacterial polymers are potentially useful in healthcare faciilties to reduce the transmission of pathogens between people and the environment.